LargeV Instrument’s IPO on STAR Board Halted Following Filing and Sponsorship Withdrawal
The initial public offering (IPO) of LargeV Instrument Corp., Ltd to the Shanghai Stock Exchange’s...
Enhertu Shows 58.3% Response Rate in Phase II Lung Cancer Study, AstraZeneca and Daiichi Sankyo Report
The Phase II DESTINY-Lung05 study results for Enhertu (trastuzumab deruxtecan), an antibody-drug conjugate co-developed by...
Yantai Dongcheng Secures Approval for Phase I Study of 68Ga-LNC1007 in Singapor
Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675) has received approval from the Health Sciences...
Sino Biopharmaceutical to Present Phase II Data for Garsorasib at AACR 2024
Sino Biopharmaceutical Ltd. (HKG: 1177) announced that it will present the results of a Phase...
STRATA Skin Sciences Renews Exclusive Distribution Deals in China and Japan
STRATA Skin Sciences Inc. (NASDAQ: SSKN), a U.S.-based dermatology and plastic surgery firm, has announced...
Aptar Pharma Secures NMPA Approval for Airless Drug Delivery System in Chin
Aptar Pharma, a U.S.-based company, announced that its Mezzo+ CS (China Support) Airless dispensing solution...
BIO’s Chief Lobbyist Nick Shipley Resigns Amid Controversy Over WuXi AppTec
Nick Shipley, the chief lobbyist for the U.S.-based Biotechnology Innovation Organization (BIO), has resigned from...
Roche Secures CE Mark for Ventana HER2 Test, Enhancing Access to AstraZeneca’s Enhertu
Roche (SWX: ROG), based in Switzerland, has received CE marking from the European Commission (EC)...
Pfizer Reports Positive Phase III Results for RSV Vaccine Abrysvo in Younger Adults
Pfizer (NYSE: PFE) has announced interim results from a Phase III trial evaluating its respiratory...
Boehringer Ingelheim’s Shanghai Unit Secures EMA and FDA Approval for Biopharmaceutical Supply
Germany-based Boehringer Ingelheim has announced that its Shanghai-based Contract Manufacturing Organization (CMO), Boehringer Ingelheim Biopharmaceuticals...
Sanofi Extends Collaboration with Nurix Therapeutics, Targeting STAT6 in Type 2 Inflammation
France’s Sanofi (NASDAQ: SNY) has announced an extension of its 2019 collaboration with Nurix Therapeutics...
Genesis MedTech Secures Hundreds of Millions in Funding to Boost R&D and Manufacturing in China
Singapore-based medical device company Genesis MedTech has raised “hundreds of millions” of renminbi in a...
Jiangsu Hengrui Secures NMPA Approval for Clinical Study of SHR-A2102 and SHR-8068 in Advanced Tumors
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has received approval from the National Medical Products...
Novartis Announces Layoffs to Streamline Operations and Boost Portfolio Value
Swiss pharmaceutical giant Novartis (NYSE: NVS) is gearing up for a strategic restructuring that will...
Merck Sharp & Dohme Acquires Abceutics for Next-Generation ADC Technology
Global healthcare leader Merck, Sharp & Dohme (MSD) (NYSE: MRK) has secured a strategic acquisition...
Bayer Partners with Google Cloud to Develop AI-Powered Medical Imaging Solutions
Germany’s pharmaceutical and life sciences giant Bayer (ETR: BAYN) has joined forces with US technology...
Simcere Pharmaceutical’s SIM0500 Earns FDA Fast-Track Designation for Multiple Myeloma
Simcere Pharmaceutical Group (HKG: 2096), a leading China-based pharmaceutical company, has announced that its trispecific...
Roche’s Inavolisib Earns Priority Review Status in China for PIK3CA-Mutated Breast Cancer
Swiss pharmaceutical giant Roche (SWX: ROG) has received priority review status from China’s Center for...
Sichuan Biokin Pharmaceuticals Initiates Phase III Trial for BL-M05D1 in Esophageal Cancer
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced the commencement of patient enrollment in...
Jiangsu Hengrui Pharmaceuticals Advances Pipeline with NMPA Approvals for Three Drugs
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received clinical trial approvals from China’s National...